Exam 2012 Flashcards
The antibacterial action of azithromycin is due to its inhibition of bacterial
A. Folic acid synthesis
B. Protein synthesis
C. DNA replication
D. Cell wall synthesis
B. Protein synthesis
The antibacterial action of vancomycin is due to its inhibition of bacterial
A. Folic acid synthesis
B. Protein synthesis
C. DNA replication
D. Cell wall synthesis
D. Cell wall synthesis
Which one of the following drugs is useful for the treatment of bacterial infections due to either MRSA or VRE
A. Penicillin G Benzanthine (Bicillin)
B. Methicillin (Staphcillin)
C. Daptomycin (Cydectin)
D. Dicloxacillin (Dynapen)
C. Daptomycin (Cydectin)
Which of the following strategies is being used to develop future drugs that will combat bacterial strains resistant to current drugs
A. Develop new synthetic drugs based on old drugs
B. Search for new natural antibiotics
C. Identify new target proteins from the sequenced genomes of resistant bacteria
D. Target quorum sensing signaling between bacteria
E. All of the above
E. All of the above
An antibiotic that kills only Gram negative bacteria is classified as
A. Bacteriostatic, narrow spectrum B. Bacteriocidal, narrow spectrum C. Bacteriostatic, broad-spectrum D. Bacteriocidal, broad-spectrum E. None of the above
B. Bacteriocidal, narrow spectrum
Cancer chemotherapy targets which of the following cell cycle phases
A. DNA synthesis (S phase)
B. Mitosis (m phase)
C. Both A and B
D. Neither A nor B
C. Both A and B
Which of the following statements regarding the anticancer activity of tamoxifen(Novaldex) is true
A. Tamoxifen is an anti-androgen and inhibits synthesis of testosterone
B. Tamoxifen is a selective estrogen receptor modulator that binds to the estrogen receptor
C. Tamoxifen is a taxane and increases stability of microtubules
D. Tamoxifen is a tyrosine kinase inhibitor that blocks the epidermal growth factor receptor kinase
B. Tamoxifen is a selective estrogen receptor modulator that binds to the estrogen receptor
Which one of the following drugs is a monoclonal antibody against human epidermal growth factor receptor 2
A. Imatinib (Gleevec)
B. Gefitinib (Iressa)
C. Erlotinib (Tarceva)
D. Trastuzumab (Herceptin)
D. Trastuzumab (Herceptin)
Which of the following statements is true for cancer chemotherapeutic drugs that block DNA synthesis (s phase)
A. They may be structural analogues of nucleotides
B. They may be structural analogues of molecules needed for the synthesis of nucleotides
C. They may physically bind DNA and deform its structure
D. All of the above
D. All of the above
Inhibition of the phosphatase calcineurin is important for the immunosuppressive action of
A. Cyclosporine a (Sandimmune)
B. Tacrolimus (Prograph)
C. Both A and B
D. Neither A nor B
C. Both A and B
Azathioprine (Imuran)
A. Inhibits the immune response to foreign antigens by acting at multiple targets
B. Stimulates the response of T cells to cytokines
C. Inhibits translocation of the transcription factor NF – KB to The nucleus
D. Binds to an immunophilin to exert it’s immunosuppressive action
E. Acts as an immunosuppressive by none of the above mechanisms
E. Acts as an immunosuppressive by none of the above mechanisms
Daclizumab (Zenapax)
A. Causes cytotoxic destruction of T cells via the complement system
B. Is a purine anti-metabolite
C. Inhibits the immune response to foreign antigens by acting at multiple targets
D. Binds to immunophilin to exert its immunosuppressive action
E. Acts as an immunosuppressive by none of the above mechanisms
D. Binds to immunophilin to exert its immunosuppressive action
Mycophenolate mofetil (CellCept)
A. Inhibits phenazine monophosphate dehydrogenase
B. Simulates export of nuclear factor of activated T cells (NFAT) from the nucleus
C. Is used to prevent sensitization of Rh negative women carrying an Rh positive fetus
D. Has none of the above actions
A. Inhibits phenazine monophosphate dehydrogenase
Based on the FDA’s drug and pregnancy rating scale, a category X-drug
A. Can be consumed only during the latter half of pregnancy
B. Is contraindicated during pregnancy
C. Shows no risks in animal models
D. Shows no risks and controlled studies in humans
B. Is contraindicated during pregnancy
A pregnant woman consumes a teratogenic agent during week 30 to 35 of fetal development. Which one of the following fetal defects is most likely to occur?
A. Growth retardation
B. Heart defects
C. Craniofacial defects
D. Vision impairment
A. Growth retardation
